
    
      PRIMARY OBJECTIVES:

      I. To evaluate the feasibility and biodistribution of 68Ga-DOTA-Bombesin (BAY 86-7548 or
      68Ga-DOTA RM2).

      OUTLINE:

      Patients receive 68Ga-DOTA-Bombesin intravenously (IV) and then undergo PET/MRI approximately
      1 hour later.

      After completion of study, patients are followed up at 24 hours and 1 week.
    
  